{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:45:43Z","timestamp":1789962343838,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pathol.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:57:55Z","timestamp":1764086275000},"page":"298-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Measurable Residual Disease detection in acute lymphoblastic leukaemia: comparison between targeted NGS and ASO-RQPCR"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8700-6354","authenticated-orcid":false,"given":"Jared","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-516X","authenticated-orcid":false,"given":"Royston","family":"Ponraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umma","family":"Habiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"Leyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby N.","family":"Trahair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-3852","authenticated-orcid":false,"given":"Michelle J.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.09.009_bib1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737159.2017.1377073","article-title":"An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia","volume":"17","author":"Nunes","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.pathol.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41375-024-02272-0","article-title":"Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines","volume":"38","author":"van der Velden","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.009_bib3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4065\/80.11.1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pathol.2025.09.009_bib4","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3390\/cancers13081847","article-title":"Minimal residual disease in acute lymphoblastic leukemia: current practice and future directions","volume":"13","author":"Contreras","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.pathol.2025.09.009_bib6","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.009_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2025.09.009_bib8","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1182\/bloodadvances.2021005576","article-title":"An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL","volume":"5","author":"Greenwood","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2025.09.009_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2009.07941.x","article-title":"Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993","volume":"148","author":"Patel","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2025.09.009_bib11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.009_bib12","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.009_bib14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.pathol.2024.04.012","article-title":"Laboratory validation and clinical utility of next-generation sequencing-based IGH\/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology","volume":"56","author":"Ma","year":"2024","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2025.09.009_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12308-023-00544-9","article-title":"Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease","volume":"16","author":"Momen","year":"2023","journal-title":"J Hematop"},{"key":"10.1016\/j.pathol.2025.09.009_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jmoldx.2021.01.009","article-title":"Validation of a PCR-based next-generation sequencing approach for the detection and quantification of minimal residual disease in acute lymphoblastic leukemia and multiple myeloma using gBlocks as calibrators","volume":"23","author":"Van der Straeten","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.pathol.2025.09.009_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2141.2009.07744.x","article-title":"Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia","volume":"146","author":"Sutton","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.09.009_bib18","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/s41375-024-02265-z","article-title":"The gray area of RQ-PCR-based measurable residual disease: subdividing the \u201cpositive, below quantitative range\u201d category","volume":"38","author":"Kotrova","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.009_bib19","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/ncomms7604","article-title":"Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia","volume":"6","author":"Ma","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2025.09.009_bib20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.009_bib21","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","article-title":"Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods","volume":"6","author":"Kotrov\u00e1","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2025.09.009_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-143416","article-title":"Minimal residual disease detection in adults with acute lymphoblastic leukemia by next generation sequencing: impact on clinical outcomes","volume":"136","author":"Cervantes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.009_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.13142","article-title":"Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia","volume":"168","author":"Sutton","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.09.009_bib24","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.009_bib25","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/bmt.2017.16","article-title":"Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL","volume":"52","author":"Kotrova","year":"2017","journal-title":"Bone Marrow Transplant"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:13:18Z","timestamp":1773951198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302525003447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0031302525003447"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.09.009","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable Residual Disease detection in acute lymphoblastic leukaemia: comparison between targeted NGS and ASO-RQPCR","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}